Jeong, T.-J.; Lee, H.-T.; Gu, N.; Jang, Y.-J.; Choi, S.-B.; Park, U.-B.; Lee, S.-H.; Heo, Y.-S.
The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. Biomedicines 2022, 10, 3154.
https://doi.org/10.3390/biomedicines10123154
AMA Style
Jeong T-J, Lee H-T, Gu N, Jang Y-J, Choi S-B, Park U-B, Lee S-H, Heo Y-S.
The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. Biomedicines. 2022; 10(12):3154.
https://doi.org/10.3390/biomedicines10123154
Chicago/Turabian Style
Jeong, Tae-Jun, Hyun-Tae Lee, Nahyeon Gu, Yu-Jeong Jang, Seung-Beom Choi, Ui-Beom Park, Sang-Hyung Lee, and Yong-Seok Heo.
2022. "The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy" Biomedicines 10, no. 12: 3154.
https://doi.org/10.3390/biomedicines10123154
APA Style
Jeong, T.-J., Lee, H.-T., Gu, N., Jang, Y.-J., Choi, S.-B., Park, U.-B., Lee, S.-H., & Heo, Y.-S.
(2022). The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. Biomedicines, 10(12), 3154.
https://doi.org/10.3390/biomedicines10123154